Followers | 229 |
Posts | 14659 |
Boards Moderated | 1 |
Alias Born | 03/29/2014 |
Wednesday, January 09, 2019 7:36:28 PM
I am by no means an expert on the nitty gritty of the science, but would add this to the conversation.
L is made from the tumor and of course, the leukepheresis material. For the P3 trial, they use the newly diagnosed tumor - so basically, the first or initial tumor. I think from that tumor material there are likely less neoantigens present because as I understand it, those develop later, as the tumor mutates. The antigens become less and less like self in the next generation tumors, and what develops instead are the neoantigens.
So... for some of the patients, L might work really well on the first tumors, especially if their type of GBM is more mutated, because there are more targets for the T Cells to chase after. I think that's why immunotherapy worked so well for melanoma - it was highly mutated. But for those who's GBM is less mutated, initially anyway, Prins' thinking was that by adding a CI to the treatment, they could better effect a result.
Now when it comes to Direct, it's injected directly into the tumor, which is how it obtains the antigens it tells the immune system to target. Well, most of those tumors have mutated from the original, so there are likely many neoantigens present on those tumors. So IMO, Direct is more likely to act as a neoantigent vaccine as it picks up whatever the targets are on the tumor, including whatever neoantigens are present, and takes all that to the command center.
I suppose if L were mixed with a recurrent GBM tumor, it would then contain more neoantigens as that would be a tumor that had mutated from the original one. That's how I understand it anyway.
Of course, anyone who understands the MOA better is welcome to correct me or explain it more comprehensively than I have here.
:)
Recent NWBO News
- Biophma Announces Exclusive In License for Dendritic Cell Technology, Sending Shares Higher • AllPennyStocks.com • 06/17/2024 04:40:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/04/2024 09:11:16 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 06/03/2024 09:22:55 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 05/22/2024 08:13:36 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/10/2024 09:04:57 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/01/2024 10:04:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/02/2023 01:31:35 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/16/2023 10:11:54 PM
- Epazz, Inc. (OTC Pink: EPAZ) ZenaDrone Demonstration to Defense Departments of UAE and Saudi Arabia • InvestorsHub NewsWire • 11/15/2023 12:19:31 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:30:39 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 • InvestorsHub NewsWire • 11/09/2023 01:00:34 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 Extreme Weather Demo • InvestorsHub NewsWire • 11/07/2023 12:29:43 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2023 08:36:14 PM
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM
ATWEC Announces Major Acquisition and Lays Out Strategic Growth Plans • ATWT • Jun 20, 2024 7:09 AM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM